Regeneron Pharmaceuticals Inc
LSE:0R2M
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Regeneron Pharmaceuticals Inc
LSE:0R2M
|
US |
|
APA Group
OTC:APAJF
|
AU |
|
Medallion Financial Corp
NASDAQ:MFIN
|
US |
|
I
|
Iridium Communications Inc
XBER:6IC
|
US |
|
S
|
Swiss Re AG
DUS:SR9
|
CH |
|
L
|
L'Air Liquide Societe Anonyme pour l'Etude et l'Exploitation des Procedes Georges Claude SA
SWB:AIL
|
FR |
|
OSI Systems Inc
NASDAQ:OSIS
|
US |
Wall St Price Targets
0R2M Price Targets Summary
Regeneron Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for 0R2M is 845.3 USD with a low forecast of 646.08 USD and a high forecast of 1 047.84 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is 0R2M's stock price target?
Price Target
845.3
USD
According to Wall Street analysts, the average 1-year price target for 0R2M is 845.3 USD with a low forecast of 646.08 USD and a high forecast of 1 047.84 USD.
What is the Revenue forecast for Regeneron Pharmaceuticals Inc?
Projected CAGR
5%
Over the last 14 years, the compound annual growth rate for Revenue has been 28%. The projected CAGR for the next 8 years is 5%.
What is the Gross Profit forecast for Regeneron Pharmaceuticals Inc?
Projected CAGR
5%
Over the last 14 years, the compound annual growth rate for Gross Profit has been 27%. The projected CAGR for the next 8 years is 5%.
What is the Operating Income forecast for Regeneron Pharmaceuticals Inc?
Projected CAGR
11%
The compound annual growth rate for Operating Income over the next 8 years is 11%.
What is the Pre-Tax Income forecast for Regeneron Pharmaceuticals Inc?
Projected CAGR
15%
The compound annual growth rate for Pre-Tax Income over the next 3 years is 15%.
What is the Net Income forecast for Regeneron Pharmaceuticals Inc?
Projected CAGR
8%
The compound annual growth rate for Net Income over the next 8 years is 8%.
